Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

l trial for elagolix, the  most advanced clinical program in the Company's pipeline, will fail to support the additional Phase III clinical trial required for regulatory approval; risk that the elagolix Phase III program overall will encounter delays for regulatory or other reasons; risk that the elagolix Phase III clinical program will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis or support filings for regulatory approval; risk that the uterine fibroid elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; and  risks associated with the Company's dependence on corporate collaborators for Phase III development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the rest of the Company's R & D pipeline including risk that the Company's clinical candidates will not be found to be safe and effective; risk that NBI-98854 will not proceed to later stage clinical trials and risk that the Company's clinical trials will fail to demonstrate that NBI-98854 is safe and effective; and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's repor
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... Cells (SOFCs) - Global Strategic Business Report" report to ... markets for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. ... Canada , Europe , ... and forecasts are provided for the period 2012 through 2020. ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 In November 2012, ... Benefit Risk Evaluation Report (PBRER) in a new PSUR – ... post-authorization safety benefit-risk profile of a drug. Adopted in many ... , Present a comprehensive and critical analysis of ... , Highlight any new evidence of the potential ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... 12 Masada Resource Group, LLC of,Birmingham, ... firm, has teamed with RJ Zapata & ... groups of waste management companies in the,Dominican ... electricity production facilities in the country. The,two ...
... Codexis, Inc., a leading,developer of clean technology ... named to the company,s Board of Directors. Joining,the ... Innovation and,Chemicals Technology, Shell Global Solutions, a unit ... Vice President and CFO, MySQL, a leading,open source ...
... Calif., Dec. 12 Odyssey Thera, Inc.,announced today ... granted,U.S. Patent No. 7,306,914, entitled "Protein-fragment Complementation,Assays (PCA) ... cancer,biology, immunology, infectious disease and gene therapy." This ... process., The patent describes a method for ...
Cached Biology Technology:Masada Teams With Leading Waste Management Firm to Produce Ethanol From Municipal Solid Waste in the Dominican Republic 2Rothwell, Wolf Elected to Codexis Board 2Rothwell, Wolf Elected to Codexis Board 3Odyssey Thera Granted U.S. Patent for Animal Imaging 2
(Date:8/19/2014)... to encourage healthier spending habits? A new study by ... by tracking the purchasing records in a supermarket chain ... nutritional value of foods for sale. , The researchers, ... and Brian Wansink PhD, author of Slim by Design ... Supermarkets in the Northeastern United States between January 2005 ...
(Date:8/19/2014)... not a lemur. It,s not an African Bush Baby or ... adorable and downright "cool" primate from Southeast Asia. , "It,s ... said Rafe Brown, curator-in-charge at the University of Kansas, Biodiversity ... cute, furry body; a long tail with a furry tuft ... that look a bit like the disks on the digits ...
(Date:8/19/2014)... a new implantable tissue scaffold coated with bone growth ... When applied to bone injuries or defects, this coated ... that looks and behaves just like the original tissue. ... dramatic improvement over the current standard for treating bone ... the patient,s body a painful process that does ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Engineering new bone growth 2Engineering new bone growth 3
... release has been lifted at the request of the PIO. ... or roll sideways, even though they lack flippers or fins. ... their diaphragm, pelvic, abdominal and rib muscles to shift their ... dive, toward the head when they surface and sideways when ...
... VIRGINIA KEY, FLA. Dr. Peter Glynn, a ... Marine and Atmospheric Science has been selected to receive ... recognizes extraordinary research and scholarly pursuits, and provides the ... This marks the second time Glynn, who received ...
... that help remove and transform pollutants that drain from ... know this as a result of many hours of ... very wet -- monitoring streams nationwide. Nitrogen removal ... for eutrophication the excessive growth of algae and ...
Cached Biology News:How alligators rock and roll 2How alligators rock and roll 3How alligators rock and roll 4How alligators rock and roll 5UM coral scientist Peter Glynn wins award for scholarly activity 2Streams natural filters, if not overloaded 2
... mouse-click image analysis software for microarray ... the solution for high quality and ... is empowered with VigeneTechs robust algorithms, ... 2D-curve fitting background correction and dust ...
fully automated system for the processing of microarrays on microscope slides...
... Rabbit, and media. Cryo-preserved cells in medium ... passage 25 (approx), supplied with kit (500 ... supplied as a long-term culture, and is ... of continuous growth from the date supplied, ...
... The MagneGST™ Protein Purification System ... method for the purification of glutathione-S-transferase ... particles (MagneGST™ Particles) are used to ... crude or cleared lysate using either ...
Biology Products: